Abstract

Locally advanced pancreatic cancer (LAPC) is a lethal disease and neoadjuvant chemotherapy and conversional resection is shown to provide the best survival for LAPC patients. Irreversible electroporation (IRE) is a new and effective method for the treatment of LAPC. This study aimed to compare the long-term survival of LAPC patients after neoadjuvant chemotherapy followed by conversional resection and IRE. A total of 140 LAPC patients were included from August 2015 to March 2020. The survival outcomes of patients after treatment with chemotherapy, chemotherapy combined with conversional resection or IRE were analyzed and compared. Patients in these three groups had similar clinical and pathological characteristics. Patients in the resection and IRE groups had similar median OS time (resection group vs. IRE group: 25.3 months vs. 26.0 months, P>0.050), which was significantly longer than that of the chemotherapy group (8.7 months, P<0.001). Additionally, patients in the resection and IRE groups had a median PFS of 10.6 and 12.0 months, respectively. Also, they were significantly higher than that of patients in the chemotherapy group. Chemotherapy combined with conversional resection and IRE was identified as significant prognostic factors for OS and PFS in LAPC patients. It was shown that compared with neoadjuvant chemotherapy followed by surgical resection, chemotherapy and IRE provided similar OS and PFS for LAPC patients with minimal invasion. This combination therapy may be a suitable treatment for LAPC patients.

Highlights

  • Pancreatic cancer is the most lethal gastrointestinal cancer

  • 140 patients was included into this study, including 31 patients who received chemotherapy, 45 patients who received neoadjuvant chemotherapy and conversional resection, and 64 patients who received combination therapy of chemotherapy and Irreversible electroporation (IRE) (IRE group)

  • Compared with tumors in the chemotherapy group, those in the resection and IRE groups were more likely to be smaller than 4 cm

Read more

Summary

Introduction

Pancreatic cancer is the most lethal gastrointestinal cancer. Surgical resection, which represents the only path to cure, is suitable for only 20% of all patients [1]. As a major part of this disease, locally advanced pancreatic cancer (LAPC) has been classified as unresectable cases with conventional surgical techniques. The optimal treatment for LAPC remains an open research question, given the lack of prospective studies of the latest chemotherapy regimens. The development of chemotherapy provided survival benefit for LAPC, the survival of LAPC after chemotherapy was unsatisfied [2]. Additional studies are underway to further delineate the chemotherapy that provides more survival benefits

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call